SSR-180,711
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (4-bromophenyl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| ATC code | ? |
| PubChem | CID 9928899 |
| Chemical data | |
| Formula | C14H21BrN2O2 |
| Mol. mass | 329.232 |
|
|
 (what is this?) (verify) |
|
SSR-180,711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.[3][4]
References
- ^ Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C. et al. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology 32 (1): 17–34. doi:10.1038/sj.npp.1301188. PMID 16936709.
- ^ Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C. et al. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology 32 (1): 1–16. doi:10.1038/sj.npp.1301189. PMID 17019409.
- ^ Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry 63 (1): 92–97. doi:10.1016/j.biopsych.2007.04.034. PMID 17601496.
- ^ Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia". Neuropsychopharmacology 34 (7): 1753–1763. doi:10.1038/npp.2008.232. PMID 19158670.
|
||||||||||||||||||||||||||||||||
|
|||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Read in another language
This page is available in 1 language
